Evidence map›Paper›PMID 40698820›Full record

ArticleAntimicrobial agents and chemotherapy2025

Assessment of TB47 as a potential novel therapeutic agent:

Gabriel Henrique Fioroni Furlan, Diego Augusto Souza Oliveira, Daniele Ferreira De Faria Bertoluci, Tiago Araujo Gomes, Jonatas Perico, Bruna Leticia Martins, Dejair Caetano Do Nascimento, Suzana Madeira Diorio, Cleverson Teixeira Soares, Shuai Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gabriel Henrique Fioroni FurlanSão Paulo State University (UNESP), Medical School, São Paulo, Brazil.ORCID 0000-0002-5784-9959
Diego Augusto Souza OliveiraOswaldo Cruz Institute, Fiocruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.
Daniele Ferreira De Faria BertoluciLauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
Tiago Araujo GomesOswaldo Cruz Institute, Fiocruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.
Jonatas PericoSão Paulo State University (UNESP), Medical School, São Paulo, Brazil.
Bruna Leticia MartinsSão Paulo State University (UNESP), Medical School, São Paulo, Brazil.
Dejair Caetano Do NascimentoLauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
Suzana Madeira DiorioLauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
Cleverson Teixeira SoaresLauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
Shuai WangInstitute of Drug Discovery, State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Tianyu ZhangInstitute of Drug Discovery, State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.ORCID 0000-0001-5647-6014
Patricia Sammarco RosaLauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
Flavio Alves Lara *Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.ORCID 0000-0002-2717-6597
Ana Carla Pereira Latini *Lauro de Souza Lima Institute, Bauru, São Paulo, Brazil.ORCID 0000-0002-5784-9959

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 303051/2021-3Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E_18/2022CNEFundação de Amparo à Pesquisa do Estado de São Paulo 2019/17833-1National Key Research and Development Program of China 2021YFA1300900
6 · The paper itself

Abstract

Leprosy is a chronic infectious disease caused by

Indexed as

Leprostatic AgentsLeprosyMycobacterium lepraeAnimalsClofazimineDapsoneDrug Therapy, CombinationFemaleMiceMice, Inbred BALB CMicrobial Sensitivity TestsRifampinClofazimineDapsoneLeprostatic AgentsRifampinleprosy treatmentmultidrug therapymycobacterial ETC inhibitorssynergistic effect

Identifiers

PMID40698820
PMCPMC12406668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.